AltruBio

2024 . 05 . 01

AltruBio to Participate in Upcoming May 2024 Medical Conferences

2024 . 03 . 12

2023 ISPE annual meeting─Dr. Judy Chou Keynote Speech: The Pursuit of Excellence in Novel Therapeutic Development

2024 . 01 . 12

Investor's Business Daily─Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

2023 . 12 . 07

AltruBio Announces Enrollment of First Patient in Phase 2 Clinical Program of ALTB-268 for the Treatment of Ulcerative Colitis

2023 . 10 . 15

ISPE─ISPE Announces Leaders from Health Canada, AltruBio, AstraZeneca, Gilead, Lonza, Lyndra, and More to Speak at the 2023 ISPE Annual Meeting & Exp

2023 . 09 . 26

AltruBio Announces FDA Clearance of IND Application for Immune Checkpoint Enhancer ALTB-268 to initiate a Phase 2 Clinical Trial for the Treatment of Ulcerative Colitis

2023 . 09 . 21

STIFEL Financial Corp.─Virtual 2023 Stifel Immunology and Inflammation Summit

2023 . 08 . 01

AltruBio Announces Positive Topline Data from Phase 1 Trial of Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

2023 . 06 . 15

AltruBio to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting

2023 . 06 . 08

San Francisco Business Times─What’s one thing Bay Area needs for Biotech? CEOs let us know

2023 . 05 . 31

AltruBio to Present at the 2023 BIO International Convention

2023 . 05 . 22

Brilliance Within Coaching and Consulting─Breakthroughs and Belief: Life in BioTech – with Dr. Jesse Hall

2023 . 05 . 08

AltruBio Announces Poster Presentation at Digestive Disease Week Conference 2023

2023 . 04 . 05

Genetic Engineering & Biotechnology News─Making the Transition from Academia to CEO

2023 . 03 . 09

AltruBio Announces Panels and Presentations at Three March Healthcare Conferences

2023 . 03 . 03

San Francisco Business Times─Major Breakthroughs Achieved by Bay Area Women – Led Biotech Companies

2023 . 01 . 23

AltruBio Announces First Participant Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis

2023 . 01 . 19

AltruBio Announces Poster Presentation on Immune Checkpoint Enhancer, ALTB-168 at Crohn’s & Colitis Congress 2023

2023 . 01 . 19

Patient Worthy─AltruBio’s Dr. Jesse Hall Discusses Data on ALTB-168 for Acute GvHD

2023 . 01 . 09

Scrip Pharma Intelligence─What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering

2023 . 01 . 05

AltruBio to Present at Biotech Showcase™ 2023

2022 . 12 . 10

AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

2022 . 12 . 08

AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases

2022 . 12 . 06

AltruBio Announces FDA Clearance of IND Application for ALTB-268, a Next-Generation Immune Checkpoint Enhancer for the Treatment of Ulcerative Colitis

2022 . 12 . 03

Life Science Leader─Industry outlook 2023

2022 . 11 . 15

Linkedin─Developing Novel Treatments for Immunological Disorders

2022 . 11 . 08

AltruBio to Present at Stifel 2022 Healthcare Conference

2022 . 11 . 03

AltruBio to Present New Phase 1b Data Evaluating Neihulizumab (ALTB-168) in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022

2022 . 11 . 01

AltruBio President and CEO Judy Chou Appointed to the Governing Board of California’s Stem Cell & Gene Therapy Agency

2022 . 10 . 11

Pharma’s almanac─What key indicators do you look at to predict the future of this industry

2022 . 10 . 03

CIRM─Judy Chou, Ph.D., Appointed to Governing Board of California’s Stem Cell & Gene Therapy Agency

2022 . 09 . 16

AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

2022 . 09 . 16

BioSpace─AltruBio President and CEO Judy Chou to Participate at the Longwood Healthcare Leaders Fall Webconference

2022 . 08 . 11

Labiotech.eu─ Top 10 biotech companies in Taiwan

2022 . 07 . 13

Podcast─Identifying Targets on Problematic T Cells to Treat Immunological Diseases with Dr. Judy Chou AltruBio

2022 . 06 . 23

Bioprocess Online─Overcoming Platform Inefficiencies In mAb Manufacturing

2022 . 06 . 06

AltruBio to Present at the 2022 BIO International Convention

2022 . 05 . 12

AltruBio Announces Completion of Enrollment in Phase 1 Clinical Study of Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

2022 . 03 . 17

BioProcess International─Manufacturing must align with new modalities to drive efficiency, AltruBio

2022 . 03 . 11

AltruBio to Present at BioProcess International US West 2022

2022 . 03 . 08

BioSpace─Three Influential Women of Biopharma Breaking Down the Executive Barrier

2022 . 03 . 01

Scrip Asks ─ What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances

2022 . 02 . 07

AltruBio to Present at BIO CEO & Investor Conference

2022 . 01 . 18

BioSpace ─ BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

2022 . 01 . 07

AltruBio to Present at Biotech Showcase™ 2022

2022 . 01 . 06

BioSpace ─ Top Life Sciences Startups to Watch in 2022

2021 . 12 . 01

Life Science Leader─What Trends Are 9 Biopharma CEOs Paying Attention To?

2021 . 10 . 12

Podcast─CMC Developability Assessments For Rapid Ph.1 Entry With AltruBio's Gene Lee, Ph.D.

2021 . 10 . 06

AltruBio to Present Abstract on Checkpoint Regulator Neihulizumab as a Novel Therapy for Immunological Diseases at the B&T Cell-Mediated Autoimmune Disease Drug Development Virtual Summit

2021 . 10 . 02

BioPharm International─Trends in Outsourcing of Bioprocess Development

2021 . 09 . 30

Bioprocess Online─mAb 2.0 For Psoriatic Arthritis

2021 . 09 . 20

Podcast─From Bayer To Startup Bio With AltruBio's Dr. Judy Chou

2021 . 09 . 13

AltruBio Continues to Strengthen Management Team With the Appointment of Jesse Hall, M.D., as Chief Medical Officer

2021 . 09 . 13

Fierce Biotech─AltruBio snags a CMO after pivot from oncology to immunology

2021 . 09 . 01

Life Science Leader─Companies To Watch: AltruBio

2021 . 08 . 09

AltruBio Strengthens Management Team With Appointment of Jeroen Grasman as Chief Financial Officer

2021 . 04 . 15

ALTRUBIO RAISES $63 MILLION SERIES A ROUND TO CONTINUE ITS COMPANY TRANSFORMATION

2021 . 04 . 15

Endpoints News─After a major facelift, AltruBio says it's ready for a pivotal fight against graft-versus-host disease

2021 . 04 . 15

Fierce Biotech─New name, new board, new focus: AltruBio relaunches with $63M series A

2021 . 03 . 08

AltruBio’s Neihulizumab Granted Fast Track Designation by the FDA for Steroid Refractory Acute Graft Versus Host Disease

2021 . 01 . 11

AltruBio to present at Biotech Showcase Digital 2021.

2020 . 11 . 24

AltruBio Presented its Novel PSGL-1 Agonist Antibody Program for Immunological Diseases at FOCIS and Presented its Phase 2a Psoriatic Arthritis study results for lead molecule, Neihulizumab (AbGn-168H), at ACR.

2020 . 09 . 29

AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.

2020 . 07 . 01

AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a results

2020 . 06 . 29

AltruBio Inc. presented AbGn-107 Phase 1a chemo-refractory GI cancer results at ASCO-GI 2020

2020 . 06 . 18

AltruBio’s presentation on Neihulizumab Phase 2a Ulcerative colitis results selected as Poster of Distinction at Digestive Disease Week (DDW) 2020

2020 . 06 . 15

AbGenomics Holding Inc. Announces Company Name Change to AltruBio Inc.

2019 . 12 . 06

The Business Journals─Bayer site head in Berkeley jumps to Peninsula cancer drug developer

2019 . 12 . 05

Abgenomics welcomes Dr. Judy Chou as new President/CEO

News & Events